Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer

The Pharmacogenomics Journal volume 15, pages 77–83 (2015)Cite this article

Subjects

Abstract

Epidermal growth factor receptor (EGFR) activation by radiation leads to increased cell proliferation and acts as a radioresistance mechanism. Neoadjuvant chemoradiation is the standard of care for locally advanced rectal cancer, and to date, no biomarkers of response have been found. We analyzed polymorphisms in the EGFR and its ligands, DNA repair genes and the thymidylate synthase in 84 stages II and III rectal cancer patients treated with neoadjuvant capecitabine plus radiotherapy. The rs11942466 polymorphism in the amphiregulin (AREG) gene region was associated with a pathological complete response (ypCR) (odds ratio: 0.26; 95% confidence interval: 0.06–0.79; P=0.014). The rs11615 C>T polymorphism in the ERCC1 gene also correlated with the ypCR as no patients with a C/C genotype achieved ypCR; P=0.023. This is the first work to propose variants within the AREG and the ERCC1 genes as promising predictive biomarkers of ypCR in rectal cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731–1740.

    Article  CAS  PubMed  Google Scholar 

  2. Belluco C, De Paoli A, Canzonieri V, Sigon R, Fornasarig M, Buonadonna A et al. Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies. Ann Surg Oncol 2011; 18: 3686–3693.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012; 13: 579–588.

    Article  CAS  PubMed  Google Scholar 

  4. Longley DB, Harkin DP, Johnston PG . 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330–338.

    Article  CAS  PubMed  Google Scholar 

  5. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ et al. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63: 2898–2904.

    CAS  PubMed  Google Scholar 

  6. Kawakami K, Omura K, Kanehira E, Watanabe Y . Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 1999; 19: 3249–3252.

    CAS  PubMed  Google Scholar 

  7. Lamas MJ, Duran G, Gomez A, Balboa E, Anido U, Bernardez B et al. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. Int J Radiat Oncol Biol Phys 2012; 82: 138–144.

    Article  CAS  PubMed  Google Scholar 

  8. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001; 19: 1779–1786.

    Article  CAS  PubMed  Google Scholar 

  9. Paez D, Salazar J, Pare L, Pertriz L, Targarona E, del Rio E et al. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes. Int J Radiat Oncol Biol Phys 2011; 81: 1319–1327.

    Article  CAS  PubMed  Google Scholar 

  10. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L . Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999; 5: 2884–2890.

    CAS  PubMed  Google Scholar 

  11. Clancy C, Burke JP, Coffey JC . KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. Surg Oncol 2013; 22: 105–111.

    Article  PubMed  Google Scholar 

  12. Liu W, Innocenti F, Wu MH, Desai AA, Dolan ME, Cook EH Jr. et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005; 65: 46–53.

    CAS  PubMed  Google Scholar 

  13. Spindler KL, Nielsen JN, Lindebjerg J, Jakobsen A . Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors. Dis Colon Rectum 2007; 50: 1363–1369.

    Article  PubMed  Google Scholar 

  14. Moriai T, Kobrin MS, Hope C, Speck L, Korc M . A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci USA 1994; 91: 10217–10221.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hsieh YY, Tzeng CH, Chen MH, Chen PM, Wang WS . Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy. Cancer Sci 2012; 103: 791–796.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ et al. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clin Cancer Res 2011; 17: 5161–5169.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002; 359: 397–401.

    Article  CAS  PubMed  Google Scholar 

  18. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680–2686.

    Article  CAS  PubMed  Google Scholar 

  19. Gregory Warnes, with contributions from Gregor Gorjanc, Friedrich Leisch and Michael Man. Population Genetics 2012.

  20. Akaike H . A new look at the statistical model identification. IEEE Trans Automat Contr 1974; AC 19: 716–723.

    Article  Google Scholar 

  21. Dudbridge F, Koeleman BP . Rank truncated product of P-values, with application to genomewide association scans. Genet Epidemiol 2003; 25: 360–366.

    Article  PubMed  Google Scholar 

  22. Hothorn T, Hornik K, Zeileis A . Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat 2006; 15: 651–674.

    Article  Google Scholar 

  23. Kriegs M, Kasten-Pisula U, Rieckmann T, Holst K, Saker J, Dahm-Daphi J et al. The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. DNA Repair (Amst) 2010; 9: 889–897.

    Article  CAS  Google Scholar 

  24. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999; 10: 2493–2506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Contessa JN, Hampton J, Lammering G, Mikkelsen RB, Dent P, Valerie K et al. Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 2002; 21: 4032–4041.

    Article  CAS  PubMed  Google Scholar 

  26. Jedlinski A, Ansell A, Johansson AC, Roberg K . EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines. J Oral Pathol Med 2013; 42: 26–36.

    Article  CAS  PubMed  Google Scholar 

  27. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009; 27: 5068–5074.

    Article  CAS  PubMed  Google Scholar 

  28. Sebio A, Paez D, Salazar J, Berenguer-Llergo A, Pare-Brunet L, Lasa A et al. Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan. Pharmacogenomics J 2013; 14: 256–262.

    Article  PubMed  Google Scholar 

  29. The ENCODE project consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 2012; 489: 57–74.

    Article  PubMed Central  Google Scholar 

  30. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H . X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999; 5: 2948–2953.

    CAS  PubMed  Google Scholar 

  31. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 2000; 9: 843–847.

    CAS  PubMed  Google Scholar 

  32. Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TD et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 2000; 21: 965–971.

    Article  CAS  PubMed  Google Scholar 

  33. Rzeszowska-Wolny J, Polanska J, Pietrowska M, Palyvoda O, Jaworska J, Butkiewicz D et al. Influence of polymorphisms in DNA repair genes XPD, XRCC1 and MGMT on DNA damage induced by gamma radiation and its repair in lymphocytes in vitro. Radiat Res 2005; 164: 132–140.

    Article  CAS  PubMed  Google Scholar 

  34. Cornetta T, Festa F, Testa A, Cozzi R . DNA damage repair and genetic polymorphisms: assessment of individual sensitivity and repair capacity. Int J Radiat Oncol Biol Phys 2006; 66: 537–545.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Instituto de Salud Carlos III (FIS/1101711, CM11/00102 to Ana Sebio). We thank Carolyn Newey for language editing.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Hospital de la Santa Ceu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

    A Sebio, D Páez, M Tobeña, M Martín-Richard, I Sullivan & A Barnadas

  2. Department of Genetics, Hospital de la Santa Ceu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

    J Salazar, E del Río & M Baiget

  3. U-705 CIBERER, Barcelona, Spain

    J Salazar & M Baiget

  4. IDIBELL–Institut Català d’Oncologia, Barcelona, Spain

    A Berenguer-Llergo

  5. Department of Surgery, Hospital de la Santa Ceu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

    E Targarona

  6. Department of Radiotherapy, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

    J Balart

Authors
  1. A Sebio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Salazar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Páez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Berenguer-Llergo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E del Río
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Tobeña
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Martín-Richard
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E Targarona
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J Balart
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Baiget
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Barnadas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Páez.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sebio, A., Salazar, J., Páez, D. et al. EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer. Pharmacogenomics J 15, 77–83 (2015). https://doi.org/10.1038/tpj.2014.33

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2014.33

This article is cited by

Search

Advanced search

Quick links